Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus.

نویسندگان

  • José A Spoelstra
  • Ronald P Stolk
  • Dan Cohen
  • Olav H Klungel
  • Joëlle A Erkens
  • Hubertus G M Leufkens
  • Diederick E Grobbee
چکیده

BACKGROUND Several studies have indicated that type 2 diabetes mellitus is more common among schizophrenic patients than in the general population. In this study, we investigated whether the use of antipsychotic drugs in patients with diabetes leads to worsening of glycemic control. METHOD In this cohort study, patients with newly diagnosed type 2 diabetes were selected from the PHARMO Record Linkage System, which comprises pharmacy records for all 320000 residents of 6 Dutch cities. In total, we identified 2585 patients with incident cases of type 2 diabetes who began treatment with oral hypoglycemic agents between 1991 and 1997 and had a medication history of at least 2 years after diagnosis of diabetes. A change in treatment from oral hypoglycemic agents alone to insulin therapy (with or without continuation of oral hypoglycemic agents) was considered a proxy for deterioration of beta-cell function. We compared the incidence of initiation of insulin therapy between users and nonusers of antipsychotic drugs by performing a Cox proportional hazards model analysis. RESULTS We found an increased risk for initiation of insulin therapy at 2 years after diagnosis of diabetes in users of antipsychotics compared with nonusers; the relative hazard (hazard ratio) was 2.0 (95% CI = 1.2 to 3.3), which did not change after adjustment for potential confounders. The risk decreased in the years after diagnosis of diabetes. CONCLUSION It seems that use of antipsychotics by patients with type 2 diabetes mellitus is associated with initiation of insulin therapy (i.e., "secondary failure"), especially in the first 2 years of the disease.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Antipsychotic Medication and Diabetes Mellitus

Sir: Spoelstra and colleagues assert that antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus and speculate from their pharmacoepidemiologic study that this worsening is probably due to β-cell toxicity. While there is general agreement that exposure to antipsychotic medications (and second-generation agents in particular) may be associated with an increased risk of diab...

متن کامل

Antipsychotic medication and diabetes mellitus.

Sir: Spoelstra and colleagues assert that antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus and speculate from their pharmacoepidemiologic study that this worsening is probably due to β-cell toxicity. While there is general agreement that exposure to antipsychotic medications (and second-generation agents in particular) may be associated with an increased risk of diab...

متن کامل

Psychiatric co-morbidity & diabetes.

Diabetes mellitus as well as psychiatric disorders are common. These may occur with one another and/or one may worsen the other. Psychological stress may follow screening for diabetes, as well as when diabetes is first identified. Acting through the hypothalamo-pituitary-adrenal axis, stress may initiate or worsen hyperglycaemia. Depression may be a risk factor for the development of diabetes; ...

متن کامل

Diabetic control and atypical antipsychotics: a case report

INTRODUCTION People with schizophrenia are at increased risk of developing metabolic disturbances. This risk may be further exacerbated by the use of antipsychotic agents. Research is still ongoing to determine the metabolic impact of antipsychotics on glucose regulation. In this case report we review some of the possible mechanisms of action of antipsychotic medication on glucose regulation. ...

متن کامل

Effects of antipsychotic medications on appetite, weight, and insulin resistance.

Although clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyramidal side effects, they have serious metabolic side effects such as substantial weight gain, intra-abdominal obesity, and type 2 diabetes mellitus. Given that most patients with mental disorders face chronic, even life-long, treatment with APDs, the risks of weight gain/obesity and other metabolic...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Journal of clinical psychiatry

دوره 65 5  شماره 

صفحات  -

تاریخ انتشار 2004